Bruce Hendry

Bruce Hendry

Company: Travere Therapeutics

Job title: Executive Director


Detailing the First Non-Immunosuppressive Therapy Approved for IgAN 9:00 am

Uncovering its unique mechanism of action of blocking both endothelin and angiotensin receptors Highlighting the study design and targeted population Discussing the potential for its use in combination therapyRead more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.